-
BATTLE Results May Not Give Correct Picture Of Onyx’s Nexavar
Monday, April 19, 2010 - 11:40amAnalyst Stephen Willey of Thomas Weisel maintains his "market weight" rating on Onyx Pharmaceuticals (NASDAQ: ONXX). The 12-month target price for ONXX is set to $29. According to Thomas Weisel, an exploratory open-label trial (BATTLE) “could generate a positive tailwind for ONXX shares in the near...
Read More >> -
Concerns Surrounding High Placebo Response Rate Against ANDS’ ANA598 To Be Mitigated
Thursday, April 15, 2010 - 11:28amAnalyst Stephen Willey of Thomas Weisel maintains his "overweight" rating on Anadys Pharmaceuticals Inc (NASDAQ: ANDS). The 12-month target price for ANDS is set to $7. According to Thomas Weisel, “There had been some investor concern around the high placebo response rate observed in the placebo...
Read More >> -
Thomas Weisel Partners More Than Double InterMune (ITMN) Price Target To $55
Wednesday, March 10, 2010 - 9:15amThomas Weisel Partners analyst Stephen Willey maintained his Overweight rating for shares of InterMune, Inc. (Nasdaq: ITMN) and raised the price target from $26 to $55. The day before, a panel at the Food and Drug Administration recommended InterMune's pirfenidone for the treatment of idiopathic...
Read More >>
